Silencing of specific key m6A regulators, such as IGF2BP2/3 in lung cancer [218] and METTL3 in glioma [220], can reverse tumor radio-resistance via activation of DNA damage repair and inhibition of CSC functions. Here, IGF2BP2 is linked to neoplasm.